Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lytix Biopharma AS ( (DE:6BG) ) has issued an update.
Lytix Biopharma has completed and registered a NOK 61 million private placement of 6,826,200 new shares, increasing its share capital to NOK 7,508,820.20 divided into 75,088,202 shares. The newly issued shares are expected to be registered in the Norwegian Central Securities Depository by 15 January 2026, reinforcing the company’s funding base as it advances its clinical-stage oncology pipeline.
More about Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma AS is a clinical-stage biotech company developing host-defense peptide-derived molecules to stimulate anti-cancer immunity. Its lead product, LTX-315, is a first-in-class oncolytic molecule intended to boost anti-cancer immune responses, and the company is building a pipeline for use across multiple cancer indications and in both mono- and combination therapy settings.
Average Trading Volume: 83,447
Current Market Cap: NOK648.5M
See more data about 6BG stock on TipRanks’ Stock Analysis page.